

Annual General Meeting of the Shareholders of Molecular Partners AG

Thursday, May 11, 2017, 2:00 p.m.
SIX Swiss Exchange Convention Point Conference Center, Zurich

Resolutions

1. Approval of the Annual Report and the Annual Financial Statements for the Financial Year 2016

The shareholders of Molecular Partners AG approved the Annual Report 2016 and the Financial Statements 2016.

2. Consultative Vote on the Remuneration Report

The shareholders of Molecular Partners AG approved the Compensation Report 2016 in a consultative vote.

3. Approval of the Appropriation of Results

The shareholders of Molecular Partners AG approved the proposal of the Board of Directors to carry forward the net loss of CHF 15,975,773, thereby bringing the position loss carried forward from CHF 4,314,081 to CHF 20,289,854.

4. Discharge of the Board of Directors and the Management Board

The shareholders of Molecular Partners AG discharged the members of the Board of Directors and the members of the Management Board for their activities in the financial year 2016.

5. Re-Elections and Elections to the Board of Directors and the Compensation Committee

5.1 Re-Elections to the Board of Directors

The shareholders of Molecular Partners AG re-elected Jörn Aldag as member of the Board of Directors and Chairman; re-elected Goran Ando, Jeffrey H. Buchalter, Steven H. Holtzman, William A. Lee, Andreas Plückthun and Petri Vainio as further members of the Board of Directors, each for a term of office of one year until the conclusion of the 2018 annual general meeting.

5.2 Election to the Board of Directors

The shareholders of Molecular Partners AG elected Gwen Fyfe as a member of the Board of Directors for a term of office of one year until the conclusion of the 2018 annual general meeting.

5.3 Re-Elections to the Compensation Committee

The shareholders of Molecular Partners AG re-elected Jörn Aldag, William A. Lee and Petri Vainio, each as member of the Compensation Committee of the Board of Directors, for a term of office of one year until the conclusion of the 2018 annual general meeting.

6. Re-Election of the Statutory Auditors

The shareholders of Molecular Partners AG re-elected KPMG AG, Zurich, as statutory auditors for the financial year 2017.

7. Re-Election of the Independent Proxy

The shareholders of Molecular Partners AG re-elected, Andreas G. Keller, attorney-at-law, Zurich, as the independent proxy for a term of office until the conclusion of the 2018 annual general meeting.

8. Approval of the Compensation Amount for the Board of Directors and the Management Board

8.1 Approval of the Compensation Amount for the Board of Directors for the Next Term of Office

The shareholders of Molecular Partners AG approved the maximum aggregate amount of compensation of the eight members of the Board of Directors for the term of office from the annual general meeting 2017 until the annual general meeting 2018 of CHF 944,900.

8.2 Approval of the Fixed Compensation Amount for the Management Board from July 1, 2017 until June 30, 2018

The shareholders of Molecular Partners AG approved the maximum aggregate amount of fixed compensation for the four members of the Management Board for the period from July 1, 2017 until June 30, 2018 of CHF 1,597,449.

8.3 Approval of the Variable Compensation Amount for the Management Board for the Current Financial Year

The shareholders of Molecular Partners AG approved the maximum aggregate amount of variable compensation for the four members of the Management Board for the current financial year of CHF 1,932,971.

Schlieren, May 11, 2017

Molecular Partners AG